Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2010 February;65(1) > Minerva Chirurgica 2010 February;65(1):59-69

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CHIRURGICA

A Journal on Surgery


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,877


eTOC

 

REVIEWS  THYROID CANCER


Minerva Chirurgica 2010 February;65(1):59-69

language: English

Multi-targeted approach in the treatment of thyroid cancer

Zarebczan B., Chen H.

Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin, WI, USA


PDF  


Thyroid cancer is the most common malignancy of the endocrine system. There are several variants, ranging from well-differentiated cancers, such as papillary carcinomas, to poorly differentiated types, which carry a worse prognosis. Many patients with well-differentiated thyroid cancers are cured by surgical intervention alone, while others require adjuvant therapy. For those patients with more aggressive tumors, such as metastatic and anaplastic thyroid cancers, surgery rarely offers a definitive cure and alternative treatment methods such as chemotherapy do not improve survival. Due to the difficulty in treating aggressive thyroid cancers, other novel therapies are needed. In this paper, we will review current strategies for managing the various types of thyroid carcinomas. We will also address many of the studied genetic pathways and new therapeutic drug targets for treating individual thyroid malignancies.

top of page

Publication History

Cite this article as

Corresponding author e-mail

chen@surgery.wisc.edu